angiosarcoma (Cancer)
Information
- Disease name
- angiosarcoma
- Disease ID
- DOID:0001816
- Description
- "A vascular cancer that derives_from the cells that line the walls of blood vessels or lymphatic vessels." [url:http\://en.wikipedia.org/wiki/Hemangiosarcoma, url:https\://en.wikipedia.org/wiki/Angiosarcoma, url:https\://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C3088, url:https\://www.ncbi.nlm.nih.gov/pubmed/23327728]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03331250 | Active, not recruiting | Phase 2 | Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) | January 18, 2018 | May 31, 2025 |
| NCT02834013 | Active, not recruiting | Phase 2 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | January 30, 2017 | May 1, 2026 |
| NCT00887809 | Completed | Phase 2 | Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes | April 2009 | November 2014 |
| NCT02584309 | Completed | Phase 2 | Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | February 22, 2016 | July 17, 2022 |
| NCT04518124 | Completed | Phase 2 | Propranolol in Angiosarcoma | December 27, 2019 | October 30, 2023 |
| NCT04293289 | Completed | N/A | Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma | November 19, 2019 | December 31, 2022 |
| NCT01303497 | Completed | Phase 2 | Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas | September 10, 2010 | January 29, 2019 |
| NCT06277154 | Not yet recruiting | Phase 2 | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | February 2024 | February 2027 |
| NCT06375941 | Recruiting | Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars | March 29, 2024 | April 1, 2034 | |
| NCT01042379 | Recruiting | Phase 2 | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | March 1, 2010 | December 2031 |
| NCT03860272 | Recruiting | Phase 1 | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | April 1, 2019 | December 2026 |
| NCT04055220 | Recruiting | N/A | Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas | March 3, 2020 | October 1, 2026 |
| NCT05799612 | Recruiting | Phase 1 | Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma | March 22, 2024 | December 31, 2029 |
| NCT05859074 | Recruiting | Phase 1 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | May 4, 2023 | May 4, 2028 |
| NCT05961761 | Recruiting | Phase 2 | Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients | August 17, 2021 | December 2028 |
| NCT02212015 | Terminated | Phase 2 | Evaluation of Votrient in Angiosarcoma | July 2014 | July 1, 2020 |
| NCT01786889 | Unknown status | N/A | Identification, Molecular Epidemiology Angiosarcoma of the Liver France | June 2013 | January 2017 |
| NCT02732678 | Unknown status | Phase 1/Phase 2 | Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Trial by the French Sarcoma Group (GSF/GETO) | May 2016 | May 2019 |
| NCT02625389 | Unknown status | Phase 4 | Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. | November 29, 2017 | October 2020 |
| NCT05116800 | Withdrawn | Phase 2 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | March 1, 2022 | August 2030 |
| NCT04906876 | Withdrawn | Phase 2 | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas | September 2021 | July 2025 |
| NCT04607200 | Withdrawn | Phase 2 | AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma | February 2021 | September 13, 2021 |
- Disase is a (Disease Ontology)
- DOID:175
- Cross Reference ID (Disease Ontology)
- ICDO:9120/3
- Cross Reference ID (Disease Ontology)
- MESH:D006394
- Cross Reference ID (Disease Ontology)
- NCI:C3088
- Cross Reference ID (Disease Ontology)
- NCI:C9275
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:39000009
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0018923
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0854893
- Exact Synonym (Disease Ontology)
- hemangiosarcoma
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0200058